understand a compound's likely safety and efficacy to promote faster drug
development. In addition, because it estimates a compound's likelihood to
succeed in late stage clinical development, it facilitates earlier, more
reliable decisions on whether or not to proceed with development, thus
freeing up R&D resources to pursue more promising pathways. We believe that
the establishment of a Translational Medicine department is a significant
step towards expanding our capabilities in the development of therapies for
critically ill patients and look forward to seeing Michael's work in this
important and growing area of clinical trial design."
Dr. Cooreman most recently served as a Senior Translational Medicine
Expert, Autoimmune Diseases and Transplantation, Exploratory Clinical
Development at Novartis. Prior to joining Novartis in 2003, Michael spent
almost ten years in academic medicine, with appointments including
Associate Professor of Medicine and Staff Gastroenterologist at the
University of Amsterdam in The Netherlands and as Visiting Scientist at Mt.
Sinai School of Medicine, Department of Liver Diseases, in New York City.
Earlier in his career, he spent two years as Head of Clinical Research and
Development, Gastroenterology and Oncology at Janssen Pharmaceuticals in
Germany. Michael received certification in Germany in Internal Medicine,
Gastroenterology and Hepatology, earned an M.D. at the University of Leuven
Medical School, Belgium, and a doctorate at the University of Dusseldorf,
About Ikaria Holdings, Inc.
Ikaria Holdings, Inc. is a fully integrated biotherapeutics company
focused on the development and commercialization of innovative
pharmaceutical and biological products and drug/device combinations for the
critically ill in the hospital and ICU setting. The company's product,
INOmax(R) (nitric oxide) for inhalation, is an FDA-approved drug for the
treatment of hypoxic respiratory failure in term and near-term newborns.
TPage: 1 2 3 Related biology technology :1
. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces2
. Ikaria Founding Scientist Named 2007 MacArthur Fellow3
. Ikaria to Present at 26th Annual JPMorgan Healthcare Conference4
. Ikaria Appoints Daniel Tasse as President and Chief Executive Officer5
. Lota Zoth Elected to Ikaria Board and Named Audit Committee Chair6
. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility7
. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies8
. Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis9
. Small Bone Innovations Introduces New Distal Radius Plating System to Repair Complex Fractures10
. Advanced Instruments Introduces Worlds Fastest High Throughput Freezing Point Osmometer11
. Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology